Shots:
- The US FDA has accepted sNDA & granted priority review to finerenone for HF pts having a left ventricular ejection fraction (LVEF) of ≥40%, i.e. mildly reduced (HFmrEF) or preserved LVEF (HFpEF), with approval expected in Q3’25. Awaits authorization in China, EU & Japan, with global applications planned
- Application was backed by P-III (FINEARTS-HF) trial, a part of P-III (MOONRAKER, n=15000) study, where FINEARTS-HF assessed finerenone (QD) vs PBO in pts (n=6000) with HF as well as LVEF of ≥40%, who received diuretic therapy for ≥30 days before randomization
- Study showed improved CV outcomes. Data was presented at ESC Congress 2024 & was published in The NEJM
Ref: Bayer | Image: Bayer
Related News:- Bayer Presents P-III (QUANTI CNS) Trial Data of Gadoquatrane at European Congress of Radiology 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
